Histone deacetylases (HDACs) inhibitors
US9387209B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 2, 2013 |
| Grant date | Jul 12, 2016 |
| Priority date | — |
| Expiry date | Sep 29, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Histone deacetylases inhibitors (HDACIs) and compositions comprising the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed. In one aspect, the invention relates to a compound having the structureor a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof. In one embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is fluoro; R5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R6 is hydrogen, or a salt thereof. In another embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R5 is chloro or fluoro; and R6 is hydrogen, or a salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.